-
公开(公告)号：US20210340237A1
公开(公告)日：2021-11-04
申请号：US17229303
申请日：2021-04-13
IPC分类号： C07K16/22 , C07K16/28 , A61P27/10 , C07K14/485 , G01N33/68
摘要： The present invention relates to agents for use in the prophylactic or therapeutic treatment of myopia in a subject, wherein said agents are capable of decreasing epidermal growth factor receptor (EGFR) signaling and/or signaling of another receptor susceptible for amphiregulin in a subject in a direct or indirect manner. The present invention further relates to agents for use in the prophylactic or therapeutic treatment of hyperopia in a subject, wherein said agents are capable of increasing epidermal growth factor receptor (EGFR) signaling and/or signaling of another receptor susceptible for amphiregulin in a subject. Furthermore, the present invention relates to methods for the diagnosis of myopia or hyperopia in a subject, comprising the steps of (a) providing a biological sample from the subject; (b) determining the amphiregulin level in said sample; (c) comparing the level determined in step (b) to the amphiregulin levels found in emmetropic subjects or subjects going to be emmetropic; and (d) determining that the subject has myopia or is predisposed for the development of myopia in case the level determined in step (b) is higher than the amphiregulin levels found in emmetropic subjects or subjects going to be emmetropic; and determining that the subject has hyperopia or is predisposed for the development of hyperopia in case the level determined in step (b) is lower than the amphiregulin levels found in emmetropic subjects or subjects going to be emmetropic. Finally, the present invention relates to a method for identifying agents which associate with amphiregulin or fragments or variants thereof.
-
公开(公告)号：US11008385B2
公开(公告)日：2021-05-18
申请号：US15558139
申请日：2016-03-15
摘要： The present invention relates to agents for use in the prophylactic or therapeutic treatment of myopia in a subject, wherein said agents are capable of decreasing epidermal growth factor receptor (EGFR) signaling and/or signaling of another receptor susceptible for amphiregulin in a subject in a direct or indirect manner. The present invention further relates to agents for use in the prophylactic or therapeutic treatment of hyperopia in a subject, wherein said agents are capable of increasing epidermal growth factor receptor (EGFR) signaling and/or signaling of another receptor susceptible for amphiregulin in a subject. Furthermore, the present invention relates to methods for the diagnosis of myopia or hyperopia in a subject, comprising the steps of (a) providing a biological sample from the subject; (b) determining the amphiregulin level in said sample; (c) comparing the level determined in step (b) to the amphiregulin levels found in emmetropic subjects or subjects going to be emmetropic; and (d) determining that the subject has myopia or is predisposed for the development of myopia in case the level determined in step (b) is higher than the amphiregulin levels found in emmetropic subjects or subjects going to be emmetropic; and determining that the subject has hyperopia or is predisposed for the development of hyperopia in case the level determined in step (b) is lower than the amphiregulin levels found in emmetropic subjects or subjects going to be emmetropic. Finally, the present invention relates to a method for identifying agents which associate with amphiregulin or fragments or variants thereof.
-
3.发明申请TREATMENT OF EYE DISEASES USING ENCAPSULATED CELLS ENCODING AND SECRETING A NEUROPROTECTIVE FACTOR AND/OR AN ANTI-ANGIOGENIC FACTOR 审中-公开使用封堵细胞治疗眼部疾病，编码和分泌神经保护因子和/或抗血管生成因子公开(公告)号：US20120263794A1
公开(公告)日：2012-10-18
申请号：US13320024
申请日：2010-05-11
IPC分类号： A61K9/50 , A61P27/02 , A61K38/20 , A61K38/26 , A61K38/18 , A61K38/22 , A61K35/12 , A61K38/16
CPC分类号： A61K38/39 , A61K9/0051 , A61K9/1652 , A61K9/5036 , A61K48/00 , A61K48/005 , A61K48/0091 , A61K2035/128 , C07K14/605
摘要： The present application refers to cells, e.g. mesenchymal stem cells or mesenchymal stromal cells, or any further suitable cell, encoding and secreting a neuroprotective factor, an anti-angiogenic factor and/or any other protein or protein-like substance suitable for (intraocular) treatment of eye diseases. Such eye diseases include glaucoma and other optic nerve disorders, retinal diseases, particularly retinitis pigmentosa (RP), age-related macular degeneration (AMD) and diabetic retinopathy, etc. The cells used herein are encapsulated in a (spherical) microcapsule, preferably comprising a core and at least one surface layer, to prevent a response of the immune system of the patient to be treated. The present application also refers to the use of these (spherical) microcapsule(s) or such factors for (intraocular) treatment of eye diseases as defined herein (for the preparation of a (pharmaceutical) composition) for the treatment of such eye diseases.
摘要翻译： 本申请是指细胞，例如 或间充质干细胞或间充质基质细胞，或编码和分泌神经保护因子的任何其它合适的细胞，抗血管生成因子和/或适用于（眼内）治疗眼部疾病的任何其它蛋白质或蛋白质样物质。 这些眼睛疾病包括青光眼和其他视神经疾病，视网膜疾病，特别是视网膜色素变性（RP），年龄相关性黄斑变性（AMD）和糖尿病性视网膜病变等。本文使用的细胞被包封在（球形）微胶囊中，优选包含 核心和至少一个表面层，以防止待治疗的患者的免疫系统的反应。 本申请还涉及这些（球形）微胶囊或这些因子用于（眼内）治疗如本文定义的眼睛疾病（用于制备（药物）组合物））用于治疗这种眼睛疾病的用途。
-
公开(公告)号：US12024557B2
公开(公告)日：2024-07-02
申请号：US17229303
申请日：2021-04-13
CPC分类号： C07K16/22 , A61P27/10 , C07K14/485 , C07K16/28 , G01N33/6893 , G01N2333/71 , G01N2500/00 , G01N2800/16
摘要： The present invention relates to agents for use in the prophylactic or therapeutic treatment of myopia in a subject, wherein said agents are capable of decreasing epidermal growth factor receptor (EGFR) signaling and/or signaling of another receptor susceptible for amphiregulin in a subject in a direct or indirect manner. The present invention further relates to agents for use in the prophylactic or therapeutic treatment of hyperopia in a subject, wherein said agents are capable of increasing epidermal growth factor receptor (EGFR) signaling and/or signaling of another receptor susceptible for amphiregulin in a subject. Furthermore, the present invention relates to methods for the diagnosis of myopia or hyperopia in a subject, comprising the steps of (a) providing a biological sample from the subject; (b) determining the amphiregulin level in said sample; (c) comparing the level determined in step (b) to the amphiregulin levels found in emmetropic subjects or subjects going to be emmetropic; and (d) determining that the subject has myopia or is predisposed for the development of myopia in case the level determined in step (b) is higher than the amphiregulin levels found in emmetropic subjects or subjects going to be emmetropic; and determining that the subject has hyperopia or is predisposed for the development of hyperopia in case the level determined in step (b) is lower than the amphiregulin levels found in emmetropic subjects or subjects going to be emmetropic. Finally, the present invention relates to a method for identifying agents which associate with amphiregulin or fragments or variants thereof.
-
5.发明公开公开(公告)号：US20230145643A1
公开(公告)日：2023-05-11
申请号：US17915334
申请日：2021-03-31
CPC分类号： A61K38/1808 , A61P27/02 , A61K9/0048
摘要： The present invention relates to a pharmaceutical composition comprising an epidermal growth factor receptor (EGFR) agonist for use in the treatment of a retinal pigment epithelium (RPE) damage associated disease in a patient, wherein the EGFR agonist comprises the EGF family consensus amino acid sequence CX7CX4-5CX10-13CXCX5GXRC (SEQ ID NO: 1), wherein X is any proteogenic amino acid, wherein the RPE damage associated disease is selected from age-related macular degeneration (AMD), retinitis pigmentosa, cone-rod dystrophies or cone dystrophies, polypoidal choroidal vasculopathy, and Stargardt's disease.
-
公开(公告)号：US20190085065A1
公开(公告)日：2019-03-21
申请号：US15558139
申请日：2016-03-15
IPC分类号： C07K16/22 , C07K14/485 , C07K16/28 , G01N33/68 , A61P27/10
摘要： The present invention relates to agents for use in the prophylactic or therapeutic treatment of myopia in a subject, wherein said agents are capable of decreasing epidermal growth factor receptor (EGFR) signaling and/or signaling of another receptor susceptible for amphiregulin in a subject in a direct or indirect manner. The present invention further relates to agents for use in the prophylactic or therapeutic treatment of hyperopia in a subject, wherein said agents are capable of increasing epidermal growth factor receptor (EGFR) signaling and/or signaling of another receptor susceptible for amphiregulin in a subject. Furthermore, the present invention relates to methods for the diagnosis of myopia or hyperopia in a subject, comprising the steps of (a) providing a biological sample from the subject; (b) determining the amphiregulin level in said sample; (c) comparing the level determined in step (b) to the amphiregulin levels found in emmetropic jects or subjects going to be emmetropic; and (d) determining that the subject has myopia or is predisposed for the development of myopia in case the level determined in step (b) is higher than the amphiregulin levels found in emmetropic subjects or subjects going to be emmetropic; and determining that the subject has hyperopia or is predisposed for the development of hyperopia in case the level determined in step (b) is lower than the amphiregulin levels found in emmetropic subjects or subjects going to be emmetropic. Finally, the present invention relates to a method for identifying agents which associate with amphiregulin or fragments or variants thereof.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.013 秒)
